Patient-assigned health state utilities for depression-related outcomes: Differences by depression severity and antidepressant medications

Journal of Affective Disorders

Volumn 48, Issue 1, 1998, Pages 25-36

  Revicki, Dennis A ^a   Wood, Martha ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antidepressant treatment; Health outcome; Health state utilities; Health status assessment; Major disorder; Patient preferences

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; CONSTIPATION; COST BENEFIT ANALYSIS; DEPRESSION; DISEASE SEVERITY; DROWSINESS; DRUG INDUCED DISEASE; FEMALE; HAMILTON SCALE; HEADACHE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; NAUSEA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031938365     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00117-1     Document Type: Article

References (46)

1. Asnis G.M., Griedman J.A., Sandersan C. Suicide behaviors in adult psychiatric outpatients. I. description and prevalence. Am. J. Psychiatry. 150:1993;81-89.
2. Barry M.J., Mulley A.G., Fowler F.J., Wennberg J.W. Watchful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. J. Am. Med. Assoc. 259:1988;3010-3017.
3. Bartman, B.A., Moy, E., Slotkin, J., Revicki, D.A., Flynn, W., 1997. Computer assisted utility assessment in older patients with peripheral arterial disease. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
4. Bennett, K.J., Torrance, G.W., 1996. Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker, B. (Ed.), Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Lippincott-Raven, Philadelphia, pp. 253-266.
5. Bennett K.J., Torrance G.W., Boyle M.H., Guscott, Moran L.A. McSad mental health state utilities: results of a survey in major, uni-polar depression. Quality Life Res. 4:1995;397.
6. Broadhead E.W., Blazer D.G., George L.K.et al. Depression, disability days and days lost from work in a prospective epidemiologic survey. J. Am. Med. Assoc. 264:1990;2524-2528.
7. Feeny D.H., Torrance G.W. Incorporating utility-based quality of life assessment measures in clinical trials. Med. Care. 27(Suppl.):1989;S190-S204.
8. Gold, M.R., Siegal, J.E., Russell, L.B., Weinstein, M.C. (Eds.), 1996. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York.
9. Hamilton, M., 1996. The Hamilton Rating Scale for Depression. In: Sartorius, N., Ban, T.A. (Eds.), Assessment of Depression. Springer-Verlag, New York.
10. Hays R.D., Wells K.B., Sherbourne C.D., Rogers W., Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch. Gen. Psychiatry. 52:1995;11-19.
11. Heiligenstein J.H., Ware J.E., Beusterien K.M., Roback P.J., Andrejasich C., Tollefson G.D. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int. Psychogeriatr. 7(Suppl.):1995;125-137.
12. Kessler R.C., McGonagle K.A., Zhao S.et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch. Gen. Psychiatry. 51:1994;8-19.
13. Kiebert, G.M., 1995. Choices in Oncology: Patients' Valuations of Treatment Outcomes in Terms of Quality and Length of Life. Doctoral Thesis University of Leiden.
14. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-item short from health survey (SF-36): II. psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care. 31:1993;247-263.
15. Mendels J., Reimherr F., Marcus R.N. et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J. Clin. Psychiatry. 56(6 Suppl.):1995;30-36.
16. Monk M. Epidemiology of suicide. Epidemiol. Rev. 9:1987;51-69.
17. Montgomery S.A., Henry J., McDonald G. Selective serotonin reuptake inhibitors: met-analysis of discontinuation rates. Int. Clin. Psychopharmacol. 9:1994;47-53.
18. Nease R.F., Kneeland T., O'Connor G.T.et al. Variation in patient utilities for outcomes of the management of chronic stable angina. J. Am. Med. Assoc. 273:1995;1185-1190.
19. Ormel J., VonKorff M., Ustun B.et al. Common mental disorders and disability across cultures: results from the WHO collaborative study on psychological problems in general health care. J. Am. Med. Assoc. 272:1994;1741-1748.
20. Patrick, D.L., Mathias, S.D., Elkin, E.P. et al., 1995. Health State Preferences of Persons with Anxiety. Technology Assessment Group, San Francisco, CA.
21. Potter W.Z., Rudorfer M.V., Manji H. The pharmacologic treatment of depression. New Engl. J. Med. 325:1991;633-642.
22. Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry. 56(Suppl.):1995;12-21.
23. Pyne J.M., Patterson T.L., Kaplan R.M.et al. Preliminary longitudinal assessment of quality of life in patients with major depression. Psychopharm. Bull. 33:1997;23-29.
24. Pyne J.M., Patterson T.L., Kaplan R.M.et al. Assessment of quality of life of patients with major depression. Psychiatry Serv. 48:1997;224-230.
25. Revicki D.A. Relationship between health utility and psychometric health status measures. Med. Care. 30:1992;MS274-MS282.
26. Revicki D.A., Kaplan R.M. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Quality Life Res. 2:1993;477-487.
27. Revicki, D.A., Weinstein, M.C., Alderman, J.H. et al., 1993. Health Utility and Health Status Outcomes of Antihypertensive Treatment. Battelle Centers for Public Health Research and Evaluation, Arlington, VA.
28. Revicki D.A., Wu A.W., Murray M.I. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med. Care. 33:1995;173-182.
29. Revicki D.A., Shakespeare A., Kind P. Preferences in schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int. Clin. Psychopharmacol. 11:1996;101-108.
30. Revicki D.A., Brown R.E., Keller M.B., Gonzales J., Culpepper L., Hales R.E. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J. Clin. Psychiatry. 58:1997;47-58.
31. Rickels S., Schweizer E., Clary C.et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br. J. Psychiatry. 164:1994;802-805.
32. Sackett D.L., Torrance G.W. The utility of different health states as perceived by the general public. J. Chron. Dis. 31:1978;697-704.
33. Simon G.E., Ormel J., VonKorff M.et al. Health care costs associated with depressive and anxiety disorders. Am. J. Psychiatry. 152:1995;352-357.
34. Simon G.E., VonKorff M., Heiligenstein J.H.et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. J. Am. Med. Assoc. 275:1996;1897-1902.
35. Song F., Freemantle N., Sheldon T.et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br. Med. J. 306:1993;683-687.
36. Spitzer, R.L., Williams, J.B.W., Gibbon, M., First, M.B., 1990. User's Guide for the Structured Clinical Interview for DSM-III-R. American Psychiatric Press, Washington.
37. Stark P., Hardison C.D. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J. Clin. Psychiatry. 46(3 (Sect. 2)):1985;53-58.
38. Stewart, A.L., Ware, J.E., Sherbourne, C.D., Wells, K.B., 1992. Psychological distress/well-being and cognitive functioning measures. In: Stewart, A.L., Ware, J.E. (Eds.), Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Duke University Press, Durham, NC, pp. 102-142.
39. Torrance G.W. Utility approach to measuring health-related quality of life. J. Chron. Dis. 40:1987;593-600.
40. Torrance G.W., Feeny D. Utilities and quality-adjusted life years. Int. J. Technol. Assess. Health Care. 5:1989;559-575.
41. Tsevat J., Goldman L., Lamas G.A.et al. Functional status versus utilities in survivors of myocardial infarction. Med. Care. 29:1991;1153-1159.
42. Ware, J.E., Snow, K.K., Kosinski, M., Gandek, B., 1993. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston.
43. Weissman, M.M., 1991. Affective disorders. In: Robins, L.N., Regier, D.A. (Eds.), Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. Free Press, New York, pp. 53-80.
44. Wells K.B., Stewart A., Hays R.D.et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. J. Am. Med. Assoc. 262:1989;916-919.
45. Williams J.W. Jr., Kerber C.A., Mulrow C.D. Depressive disorders in primary care: prevalence, functional disability, and identification. J. Gen. Intern. Med. 10:1995;7-12.
46. Workman E., Short D. Atypical antidepressants versus imipramine in the treatment of major depression. J. Clin. Psychiatry. 54:1993;5-12.